ETF profile for Corgi Genomics & Precision Medicine ETF (GNMX) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
GNMX ETF Profile
| Family: |
Corgi Strategies |
| Name: |
Corgi Genomics & Precision Medicine ETF |
|
|
| Inception Date: |
6-May-2026 |
| Termination Date: |
|
| Investment Objective: |
The Fund is an exchange-traded fund ("ETF") that seeks to meet its objective by having Corgi Strategies, LLC (the "Adviser") actively manage the Fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies that enable improved disease detection, identifying and grouping patients based on genetic, molecular, or clinical characteristics to guide treatment decisions (patient stratification), targeted therapies, and data-driven healthcare. For purposes of this policy, the Fund considers the following activities: gene sequencing and analysis, bioinformatics and computational biology, molecular diagnostics and companion tests, gene editing and gene therapy platforms, targeted biologics and small molecule therapeutics, laboratory tools and reagents, clinical data platforms, and enabling services that support the discovery, development, and delivery of personalized medicine across prevention, diagnosis, and treatment. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Moderna Inc |
MRNA |
9.0900% |
| Thermo Fisher Scientific Inc |
TMO |
8.8500% |
| Vertex Pharmaceuticals Inc |
VRTX |
6.0200% |
| Illumina Inc |
ILMN |
4.8600% |
| Genmab A/S |
GMAB |
3.6400% |
| Guardant Health Inc |
GH |
3.6100% |
| Revolution Medicines Inc |
RVMD |
3.1700% |
| 10X Genomics Inc |
TXG |
3.1700% |
| Iovance Biotherapeutics Inc |
IOVA |
3.1400% |
| Incyte Corp |
INCY |
2.6600% |
|
Top 10 Holdings Weight: |
48.2% |
| Number of Holdings: |
58 |
| Shares Outstanding: |
35,000 |
| Total Net Assets: |
1,280,895 |
| NAV: |
36.56 |
| Net Expense Ratio: |
0.35% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
US |
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
|
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Domestic |
